journal article·2024-01Open access

Targeting the Mitochondrial Chaperone TRAP1 Alleviates Vascular Pathologies in Ischemic Retinopathy

So‐Yeon Kim, Nam Gu Yoon, Jin Young Im, Ji Hye Lee, Juhee Kim, Yujin Jeon, Young Jae Choi, Jong‐Hwa Lee, Akiyoshi Uemura, Dong Ho Park, Byoung Heon Kang

Advanced Science· Volume 11· Issue 2

Abstract

Abstract Activation of hypoxia‐inducible factor 1α (HIF1α) contributes to blood‐retinal barrier (BRB) breakdown and pathological neovascularization responsible for vision loss in ischemic retinal diseases. During disease progression, mitochondrial biology is altered to adapt to the ischemic environment created by initial vascular dysfunction, but the mitochondrial adaptive mechanisms, which ultimately contribute to the pathogenesis of ischemic retinopathy, remain incompletely understood. In the present study, it is identified that expression of mitochondrial chaperone tumor necrosis factor receptor‐associated protein 1 (TRAP1) is essential for BRB breakdown and pathologic retinal neovascularization in mouse models mimicking ischemic retinopathies. Genetic Trap1 ablation or treatment with small molecule TRAP1 inhibitors, such as mitoquinone (MitoQ) and SB‐U015, alleviate retinal pathologies via proteolytic HIF1α degradation, which is mediated by opening of the mitochondrial permeability transition pore and activation of calcium‐dependent protease calpain‐1. These findings suggest that TRAP1 can be a promising target for the development of new treatments against ischemic retinopathy, such as retinopathy of prematurity and proliferative diabetic retinopathy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Mitochondrial Function and Pathology · Calpain Protease Function and Regulation · Retinal Diseases and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biological Sciences Ulsan National Institutes of Science and Technology (UNIST) Ulsan 44919 Republic of Korea

SmartinBio Inc. Cheongju 28160 Republic of Korea

Department of Ophthalmology, School of Medicine Kyungpook National University, Kyungpook National University Hospital Daegu 41944 Republic of Korea

Cell & Matrix Research Institute Kyungpook National University Daegu 41944 Republic of Korea

Bioanalysis and Pharmacokinetics Research Group Korea Institute of Toxicology Daejeon 34114 Republic of Korea

Department of Human and Environment Toxicology University of Science & Technology Daejeon 34113 Republic of Korea

Department of Ophthalmology and Visual Science Nagoya City University Graduate School of Medical Sciences Nagoya 467‐8601 Japan

Funding

National Research Foundation of Korea · Korea Drug Development Fund · Ministry of Health and Welfare · Institute for Information and communications Technology Promotion

References (71)

Show source-provided references
1. 10.1016/j.cell.2012.02.03510.1016/j.cell.2012.02.035 ↗
2. 10.1016/j.cell.2016.07.00210.1016/j.cell.2016.07.002 ↗
3. 10.1038/nrm.2017.6610.1038/nrm.2017.66 ↗
4. 10.1016/j.tcb.2014.03.00510.1016/j.tcb.2014.03.005 ↗
5. 10.1016/j.cell.2007.08.02810.1016/j.cell.2007.08.028 ↗
6. 10.1074/jbc.275.5.330510.1074/jbc.275.5.3305 ↗
7. 10.1158/0008-5472.CAN-18-255810.1158/0008-5472.CAN-18-2558 ↗
8. 10.1186/1476-4598-13-14810.1186/1476-4598-13-148 ↗
9. 10.1016/j.preteyeres.2020.10088110.1016/j.preteyeres.2020.100881 ↗
10. 10.2337/dbi18-001610.2337/dbi18-0016 ↗
11. 10.1056/NEJMra100507310.1056/NEJMra1005073 ↗
12. 10.1016/S0140-6736(09)62124-310.1016/S0140-6736(09)62124-3 ↗
13. 10.1016/S0140-6736(13)60178-610.1016/S0140-6736(13)60178-6 ↗
14. 10.1038/s41580-020-0227-y10.1038/s41580-020-0227-y ↗
15. 10.1172/jci.insight.9375110.1172/jci.insight.93751 ↗
16. 10.1172/JCI4214210.1172/JCI42142 ↗
17. 10.1038/s41574-020-00451-410.1038/s41574-020-00451-4 ↗
18. 10.1016/j.ophtha.2016.06.05510.1016/j.ophtha.2016.06.055 ↗
19. 10.1016/j.ajo.2011.07.00510.1016/j.ajo.2011.07.005 ↗
20. 10.1038/s41433-018-0138-810.1038/s41433-018-0138-8 ↗
21. 10.1038/nprot.2009.18710.1038/nprot.2009.187 ↗
22. Smith L. E. · Invest Ophthalmol · 1994 · 35 · 101
23. 10.2337/db09-142010.2337/db09-1420 ↗
24. 10.1038/nrn372310.1038/nrn3723 ↗
25. 10.1073/pnas.212187511910.1073/pnas.2121875119 ↗
26. 10.1172/JCI12665510.1172/JCI126655 ↗
27. 10.1172/JCI12087910.1172/JCI120879 ↗
28. 10.1007/s00125-011-2081-010.1007/s00125-011-2081-0 ↗
29. 10.1016/j.exer.2009.12.00210.1016/j.exer.2009.12.002 ↗
30. 10.1073/pnas.92.3.90510.1073/pnas.92.3.905 ↗
31. 10.1038/s41419-021-03716-610.1038/s41419-021-03716-6 ↗
32. 10.1016/j.exer.2021.10871810.1016/j.exer.2021.108718 ↗
33. 10.1167/iovs.04-136110.1167/iovs.04-1361 ↗
34. 10.1073/pnas.152201411310.1073/pnas.1522014113 ↗
35. 10.1038/nm.205210.1038/nm.2052 ↗
36. 10.2337/diabetes.47.3.44510.2337/diabetes.47.3.445 ↗
37. 10.1167/iovs.18-2537210.1167/iovs.18-25372 ↗
38. Holash J. · Science · 1994 · 284 · 1999
39. 10.1016/j.molmed.2022.03.00410.1016/j.molmed.2022.03.004 ↗
40. 10.3390/ijms1904094210.3390/ijms19040942 ↗
41. 10.3389/fimmu.2020.60163910.3389/fimmu.2020.601639 ↗
42. 10.1167/iovs.14-1486410.1167/iovs.14-14864 ↗
43. 10.1161/ATVBAHA.117.31033710.1161/ATVBAHA.117.310337 ↗
44. 10.1016/j.cmet.2013.04.01910.1016/j.cmet.2013.04.019 ↗
45. 10.1021/ja511893n10.1021/ja511893n ↗
46. 10.1021/acs.jmedchem.2c0163310.1021/acs.jmedchem.2c01633 ↗
47. 10.1016/j.tibs.2008.08.00210.1016/j.tibs.2008.08.002 ↗
48. 10.1074/jbc.M20473320010.1074/jbc.M204733200 ↗
49. Mabjeesh N. J. · Cancer Res. · 2002 · 62 · 2478
50. 10.1016/S1074-5521(01)00056-410.1016/S1074-5521(01)00056-4 ↗
51. 10.1091/mbc.e05-08-077010.1091/mbc.e05-08-0770 ↗
52. 10.1038/s12276-019-0360-x10.1038/s12276-019-0360-x ↗
53. 10.1016/j.vph.2012.02.00910.1016/j.vph.2012.02.009 ↗
54. 10.1016/S0092-8674(02)00659-110.1016/S0092-8674(02)00659-1 ↗
55. 10.1038/nsb0402-23910.1038/nsb0402-239 ↗
56. 10.1152/physrev.00029.200210.1152/physrev.00029.2002 ↗
57. 10.1016/j.cell.2004.08.02510.1016/j.cell.2004.08.025 ↗
58. 10.1021/jacs.1c0709910.1021/jacs.1c07099 ↗
59. 10.1016/j.preteyeres.2015.06.00210.1016/j.preteyeres.2015.06.002 ↗
60. 10.1038/s41580-021-00433-y10.1038/s41580-021-00433-y ↗
61. 10.1038/s41422-020-0388-410.1038/s41422-020-0388-4 ↗
62. 10.1074/jbc.M40810020010.1074/jbc.M408100200 ↗
63. 10.1056/NEJMoa100737410.1056/NEJMoa1007374 ↗
64. 10.1542/peds.2016-005710.1542/peds.2016-0057 ↗
65. 10.1056/NEJMoa141426410.1056/NEJMoa1414264 ↗
66. 10.1007/s00125-008-1078-910.1007/s00125-008-1078-9 ↗
67. 10.15252/emmm.20181020410.15252/emmm.201810204 ↗
68. 10.1073/pnas.142376511210.1073/pnas.1423765112 ↗
69. 10.1172/JCI3761310.1172/JCI37613 ↗
70. 10.1038/nrd380110.1038/nrd3801 ↗
71. Liu X. · Bio Protoc · 2017 · 7